Literature DB >> 9389741

Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease.

C M Hogaboam1, B A Vallance, A Kumar, C L Addison, F L Graham, J Gauldie, S M Collins.   

Abstract

Inflammatory bowel disease (IBD) is characterized by altered immunoregulation and augmented intestinal synthesis of nitric oxide. The purpose of this study was to determine the effects of exogenous IL-4, introduced by a recombinant human type 5 adenovirus (Ad5) vector, on the tissue injury associated with an experimental model of colonic immune activation and inflammation. Colitis was induced in rats by the intrarectal administration of trinitrobenzene sulfonic acid (TNB) dissolved in 50% ethanol, and control rats received saline via the same route. 1 h later, all rats were randomized into two groups. The first group was injected intraperitoneally (ip) with 3.0 x 10(6) plaque forming units (PFUs) of Ad5 transfected with murine interleukin-4 (Ad5IL-4) and the second group was injected ip with the same amount of Ad5 expressing the Escherichia coli Lac Z gene (Ad5LacZ). One-half of the colitic and control rats were injected again with 3.0 x 10(6) PFUs of Ad5IL-4 or Ad5LacZ on day 3 of the 6-d study. When introduced once or twice via the peritoneal route into control rats, Ad5LacZ was localized to the serosal lining of the peritoneal cavity, the diaphragm and the liver on day 6. One or two injections of Ad5IL-4 into rats also produced measurable levels of circulating IL-4. TNB-colitis in both Ad5LacZ-treated groups was associated with pronounced elevations in serum IFN-gamma, and mucosal ulceration of the distal colon. Myeloperoxidase and inducible nitric oxide synthase II (NOS II) synthetic activity were also increased by 30- and fivefold, respectively, above control levels in the distal colon. However, two injections of Ad5IL-4 into colitic rats caused the overexpression of IL-4, and significantly inhibited tissue damage, serum and colon IFN-gamma levels and myeloperoxidase activity in the distal colon. In addition, NOS II gene expression and NOS II nitric oxide synthesis was significantly inhibited. No therapeutic effect was observed in rats injected once with Ad5IL-4. Thus, IL-4, introduced by Ad5, is therapeutic during acute inflammation in the rat colon. The therapeutic effect of IL-4 was associated with an inhibition of inducible nitric oxide expression and a reduction in nitric oxide synthesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389741      PMCID: PMC508481          DOI: 10.1172/JCI119823

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Anti-inflammatory action of IL-4. Negative regulation of contact sensitivity to trinitrochlorobenzene.

Authors:  S C Gautam; N F Chikkala; T A Hamilton
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

2.  Hapten-induced model of chronic inflammation and ulceration in the rat colon.

Authors:  G P Morris; P L Beck; M S Herridge; W T Depew; M R Szewczuk; J L Wallace
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

3.  Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease.

Authors:  K Kusugami; T Matsuura; G A West; K R Youngman; D Rachmilewitz; C Fiocchi
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

Review 4.  Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice.

Authors:  W Strober; R O Ehrhardt
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

Review 5.  The L-arginine: nitric oxide pathway, cellular transduction and immunological roles.

Authors:  S Moncada
Journal:  Adv Second Messenger Phosphoprotein Res       Date:  1993

6.  Tumour-necrosis-factor antibody treatment in Crohn's disease.

Authors:  B Derkx; J Taminiau; S Radema; A Stronkhorst; C Wortel; G Tytgat; S van Deventer
Journal:  Lancet       Date:  1993-07-17       Impact factor: 79.321

7.  Janus faces of nitric oxide.

Authors:  S H Snyder
Journal:  Nature       Date:  1993-08-12       Impact factor: 49.962

8.  Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon.

Authors:  M Mourelle; F Casellas; F Guarner; A Salas; V Riveros-Moreno; S Moncada; J R Malagelada
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

9.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

10.  Amelioration of chronic ileitis by nitric oxide synthase inhibition.

Authors:  M J Miller; H Sadowska-Krowicka; S Chotinaruemol; J L Kakkis; D A Clark
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

View more
  25 in total

1.  Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD).

Authors:  E Brandt; J F Colombel; N Ectors; L Gambiez; D Emilie; K Geboes; M Capron; P Desreumaux
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells.

Authors:  C Jobin; O Morteau; D S Han; R Balfour Sartor
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

3.  Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat.

Authors:  F F Sun; P S Lai; G Yue; K Yin; R G Nagele; D M Tong; R F Krzesicki; J E Chin; P Y Wong
Journal:  Inflammation       Date:  2001-02       Impact factor: 4.092

4.  Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.

Authors:  R Newman; N Cuan; T Hampartzoumian; S J Connor; A R Lloyd; M C Grimm
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

5.  Intestinal nematode infection ameliorates experimental colitis in mice.

Authors:  W I Khan; P A Blennerhasset; A K Varghese; S K Chowdhury; P Omsted; Y Deng; S M Collins
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Interleukin 10 gene transfer prevents experimental colitis in rats.

Authors:  G Barbara; Z Xing; C M Hogaboam; J Gauldie; S M Collins
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

7.  Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  T G Moreels; R J Nieuwendijk; J G De Man; B Y De Winter; A G Herman; E A Van Marck; P A Pelckmans
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 8.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

9.  Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis.

Authors:  A Ukil; S Maity; S Karmakar; N Datta; J R Vedasiromoni; Pijush K Das
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease.

Authors:  T T Macdonald
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.